# US 2026/0245655 A1 · Methods for determining drug candidates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0245655 A1
- Document ID: US20260245655A1
- Status: Published application
- Kind: A1
- Application number: 19/162,108
- Filed: 2024-03-07
- Published: 2026-08-20
- Earliest claimed: 2023-03-07
- Assignees: Mosaiques Diagnostics and Therapeutics AG
- Applicants: Mosaiques Diagnostics and Therapeutics AG
- Inventors: Marika MOKOU; Harald MISCHAK
- Web page: https://patentgrep.com/patent/US20260245655A1

## CPC

- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/4245: Oxadiazoles
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/566: having an oxo group in position 17, e.g. estrone
- A61K 31/5685: having an oxo group in position 17, e.g. androsterone
- C07D 215/44: with aryl radicals attached to said nitrogen atoms
- C07D 307/80: Radicals substituted by oxygen atoms
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention relates in a first aspect to a method for determining candidate molecules for treating a disease, disorder or condition associated with tissue alteration. In particular, the method refers to determining candidate molecules for treating bladder cancer in different stages of the disease, including an in silico prediction of drug response based on reversion of a disease specific molecular signature. For example, the CMap analysis is applied on data sets obtained based on proteomics and transcriptomics analyses. In a further aspect, the present invention relates to candidate molecules useful for treating said disease, disorder or condition at different stages of disease, in particular, allowing reversal of a more severe stage of disease to a more moderate stage or to stop progression to aggressive phenotypes like aggressive phenotype of bladder cancer. Finally, drug candidates useful in the treatment of said disease, in particular, the treatment of bladder cancer are provided.

## Claims

### Claim 1

A method for determining candidate molecules for treating a disease, disorder or condition associated with tissue alteration, like a tumor, in particular bladder cancer (BC) at different stages of said disease, disorder or condition comprising in silico prediction of drug response, based on reversion of a disease specific molecular signature, in particular, applying CMap analysis based on data obtained by
i) a first method of obtaining a disease, disorder or condition specific signature, like BC signatures from the altered tissue, like from BC tissue whereby a) these tissues are analyzed on proteomic differences associated with disease, disorder or condition associated progression, like tumor progression, in particular with BC progression and be detected in more than 10% of the analyzed tissue samples followed by b) identifying features characterizing different protein expression associated with the progression or the different stages of the disease, disorder or condition for providing a first data set for in silico prediction of drug response, in particular by CMap analysis;
ii) a second method of obtaining a disease, disorder or condition specific signature, like BC signatures whereby a) the cell proteome of cell lines, like tumor cell lines, in particular, BC cell lines depicting MIBC and NMIBC pathology, of different stages of progression of said disease, disorder or condition are analyzed and determining proteins demonstrating significant change in abundance between different stages of progression followed by b) comparing the protein of the cells, like the tumor cells, in particular the BC, with the tissue proteome for providing a second data set for in silico prediction of drug response, in particular by CMap analysis;
iii) a third method of obtaining a third disease, disorder or condition specific signature, like a third BC signature comprising a) obtaining a cell lines transcriptomics data set whereby cell lines of different stages of the disease, disorder or condition are analysed; b) obtaining a cell line proteomics data set whereby cell lines of different stages of the disease, disorder or condition are analysed; c) comparing the proteomics data and transcriptomic data of a) and b) for obtaining features common in both data sets; and d) from the common features obtained in c) determining features being statistically significant different in at least one of the data set of a) and b) for providing a third data set for in silico prediction of drug response, in particular by CMap analysis; and
iv) the data set obtained in each of i), ii) and iii) are analyzed by a method for in silico prediction of drug response, in particular by CMap analysis for determining candidate molecules.

### Claim 2 (depends on 1)

The method for determining candidate molecules for treating a disease, disorder or condition, associated with tissue alteration, like a tumor, in particular BC according to claim 1 wherein the disease is a tumor including solid tumors.

### Claim 3 (depends on 2)

The method according to claim 2 wherein the tumor is BC.

### Claim 4 (depends on 3)

The method according to claim 3, wherein BC progression is differentiated between non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC).

### Claim 5 (depends on 2)

The method according to claim 2 wherein the tumor is prostate cancer.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the disease, disorder or condition is heart failure.

### Claim 7 (depends on 1)

The method for determining candidate molecules for treating a disease, disorder or condition, associated with tissue alteration, like a tumor, in particular BC according to claim 1 wherein the candidate molecules are determined to allow reversal of an aggressive phenotype of the disease, disorder or condition, associated with tissue alteration, like a tumor, in particular BC.

### Claim 8 (depends on 1)

The method for determining candidate molecules for treating a disease, disorder or condition, associated with tissue alteration, like a tumor, in particular BC according to claim 1 wherein in step i) after b) the features of b) are compared with tissue transcriptomics data and/or features from tissue databases for providing features differentially expressed at the different stages of said disease, disorder or condition, like being relevant to stage progression, in particular, BC progression present in the first data set.

### Claim 9 (depends on 8)

The method for determining candidate molecules for treating a disease, disorder or condition, associated with tissue alteration, like a tumor, in particular BC according to claim 8 wherein the cell lines analyzed in method ii) are cell lines having either MIBC or NMIBC phenotype.

### Claim 10 (depends on 1)

The method for determining candidate molecules for treating a disease, disorder or condition, associated with tissue alteration, like a tumor, in particular BC according to claim 1 wherein proteins determined in step ii) included among others proteins for which disease specificity in the analysed tissue, like tumor association, is known.

### Claim 11 (depends on 1)

The method for determining candidate molecules for treating a disease, disorder or condition, associated with tissue alteration, like a tumor, in particular BC according to claim 1 wherein the tissue proteome used in step ii) is the tissue proteome of step i).

### Claim 12 (depends on 1)

The method for determining candidate molecules for treating BC according to claim 1 wherein the transcriptome in step iii) is RNA transcriptome from cell lines from urinary tract.

### Claim 13 (depends on 1)

The method for determining candidate molecules for treating a disease, disorder or condition, associated with tissue alteration, like a tumor, in particular BC according to claim 1 wherein in step iv) candidate molecules are determined by a negative enrichment score in CMap analysis.

### Claim 14 (depends on 1)

The method for determining candidate molecules according to claim 1 further comprising the step of determining data on treating the disease, disorder or condition, associated with tissue alteration of said candidate molecules determined in the present method in treating a different disease than the disease of claim 1.

### Claim 15 (depends on 1, 14)

Method for determining candidate molecules according to claim 14, wherein the step of determining data on treating a disease is a disease being a tumor and wherein the candidate molecules are known candidate molecules in treating cancer whereby said cancer is a different cancer disease different to the cancer disease of claim 1.

### Claim 16 (depends on 15)

The method for determining candidate molecules according to claim 15 wherein the disease is BC and the data determined on treating a disease are data determined with respect to a cancer other than BC and the candidate molecules are known candidate molecules in treating cancer other than BC.

### Claim 17 (depends on 1)

A candidate molecule not described for treating a disease, disorder or condition associated with tissue alteration, like a tumor, in particular BC at different stages of said disease, disorder or condition obtained by a method according to claim 1 for use in treating a disease, disorder or condition associated with tissue alteration, like a tumor, in particular BC at different stages of said disease, disorder or condition.

### Claim 18 (depends on 17)

The candidate molecule according to claim 17 for use in the treatment of BC being Cephaeline.

### Claim 19 (depends on 17)

The drug candidate according to claim 17 being a compound of general formula II
wherein
R1, R2, R4, R6 and R7 each are independently selected from H, C1-C4 alkyl, substituted C1-C4 alkyl, halogen;
R3 and R8 are each individually selected from O, OH, O C1-C4 alkyl;
----- is a single or double bond;
R5 is a compound of CHn (C1-C4) m with n and m being an integer of 0 to 3 and n+m is 3 when ----- is a single bond, and
R5 is CH2, CH C1-C4 alkyl or C(C1-C4 alkyl)2 when ----- is a double bond,
for use in the treatment of BC.

### Claim 20 (depends on 19)

The candidate molecule of general formula II for use in the treatment of BC according to claim 19 wherein R1, R2, R4, R6 and R7 are hydrogen; R3 and R8 are O and R5 is CH2
----- is a double bond, in particular, is exemestane.

### Claim 21 (depends on 19)

The candidate molecule according to claim 19 for use in treating of BC being a compound selected from the group of
v) Fluvoxamine or a derivative thereof;
vi) Amiodarone or a derivative thereof;
vii) Isradipine or a derivative thereof; or
viii) Amodiaquine or a derivative thereof.
